Avadel Pharmaceuticals Receives Buy Rating and $22 Target from Analyst

Avadel Pharmaceuticals (AVDL) has received a Buy rating and a $22 price target from analyst Raghuram Selvaraju of H.C. Wainwright. The analyst expects the company to surpass 4,000 narcolepsy patients on their therapy by the end of the following year and reach the higher end of its projected targets for this year. The average target price for AVDL is $17.13, with a high estimate of $22.00 and a low estimate of $13.00, indicating an upside of 57.98% from the current price of $10.84.